BR0209614A - Métodos para tratamento de um mamìfero sofrendo de distúrbio obsessivo-compulsivo (ocd) ou distúrbios relacionados a ocd, e para redução ou eliminação de comportamentos associados com ocd ou distúrbios relacionados a ocd em um mamìfero sofrendo de tais distúrbios - Google Patents

Métodos para tratamento de um mamìfero sofrendo de distúrbio obsessivo-compulsivo (ocd) ou distúrbios relacionados a ocd, e para redução ou eliminação de comportamentos associados com ocd ou distúrbios relacionados a ocd em um mamìfero sofrendo de tais distúrbios

Info

Publication number
BR0209614A
BR0209614A BR0209614-5A BR0209614A BR0209614A BR 0209614 A BR0209614 A BR 0209614A BR 0209614 A BR0209614 A BR 0209614A BR 0209614 A BR0209614 A BR 0209614A
Authority
BR
Brazil
Prior art keywords
ocd
related disorders
disorders
mammal suffering
obsessive
Prior art date
Application number
BR0209614-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Stephen L Dewey
Jonathan D Brodie
Charles R Ashby Jr
Original Assignee
Brookhaven Science Ass Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Ass Llc filed Critical Brookhaven Science Ass Llc
Publication of BR0209614A publication Critical patent/BR0209614A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0209614-5A 2001-05-14 2002-05-08 Métodos para tratamento de um mamìfero sofrendo de distúrbio obsessivo-compulsivo (ocd) ou distúrbios relacionados a ocd, e para redução ou eliminação de comportamentos associados com ocd ou distúrbios relacionados a ocd em um mamìfero sofrendo de tais distúrbios BR0209614A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/853,392 US6462084B1 (en) 2001-05-14 2001-05-14 Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
PCT/US2002/014344 WO2002092071A1 (en) 2001-05-14 2002-05-08 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg

Publications (1)

Publication Number Publication Date
BR0209614A true BR0209614A (pt) 2004-12-07

Family

ID=25315916

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209614-5A BR0209614A (pt) 2001-05-14 2002-05-08 Métodos para tratamento de um mamìfero sofrendo de distúrbio obsessivo-compulsivo (ocd) ou distúrbios relacionados a ocd, e para redução ou eliminação de comportamentos associados com ocd ou distúrbios relacionados a ocd em um mamìfero sofrendo de tais distúrbios

Country Status (18)

Country Link
US (2) US6462084B1 (enExample)
EP (1) EP1392273A4 (enExample)
JP (1) JP2004533445A (enExample)
KR (1) KR20040028758A (enExample)
CN (1) CN1509168A (enExample)
BR (1) BR0209614A (enExample)
CA (1) CA2446641A1 (enExample)
CZ (1) CZ20033379A3 (enExample)
HR (1) HRP20030894A2 (enExample)
HU (1) HUP0400032A3 (enExample)
IL (1) IL158761A0 (enExample)
MX (1) MXPA03010406A (enExample)
NO (1) NO20035037L (enExample)
NZ (1) NZ529613A (enExample)
PL (1) PL367362A1 (enExample)
TW (1) TWI313599B (enExample)
WO (1) WO2002092071A1 (enExample)
YU (1) YU89103A (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227052A1 (en) 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
JP2005534678A (ja) * 2002-06-27 2005-11-17 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 注意欠陥多動性障害の治療方法
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
WO2004096269A2 (en) * 2003-04-25 2004-11-11 Allergan, Inc. Botulinum neurotoxin for treating tics and obsessive compulsive behaviors
US20110275664A1 (en) * 2005-09-26 2011-11-10 The Regents Of The University Of Colorado,A Body Corporate Method for treating drug and behavioral addictions
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2790820A1 (en) * 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
AU2012345659B2 (en) 2011-12-02 2017-09-28 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014197744A1 (en) * 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN104306736A (zh) * 2014-10-31 2015-01-28 哈尔滨市海江科技开发有限公司 一种治疗疑病症的膏药及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761429A (en) 1985-07-22 1988-08-02 Kenneth Blum Enkephalinase and endorphinase inhibitors as anti-craving compositions
US5189064A (en) 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
US4786647A (en) 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US4980168A (en) 1989-10-13 1990-12-25 Natrol, Inc. Dietary supplement for children
EP0767174A1 (de) 1991-11-21 1997-04-09 Ciba-Geigy Ag Neue Aminoalkanphosphinsäuren und ihre Salze
DK0641330T3 (da) * 1992-05-20 2001-12-03 Univ Northwestern Gaba- og L-glutaminsyreanaloger til antikrampeanfaldsbehandling
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
EP0915697B1 (en) 1996-06-28 2002-09-18 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
US5776956A (en) 1996-07-30 1998-07-07 Lectec Corporation Use of cotinine in treating psychiatric disorders
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
IL135659A0 (en) 1997-10-28 2001-05-20 Schering Corp Method of reducing craving in mammals
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
MXPA01004015A (es) * 1998-10-20 2003-03-10 Johnson & Johnson Derivados anticonvulsivos utiles para el tratamiento de la dependencia, adiccion y abuso del alcohol.
MXPA01007758A (es) 1999-02-01 2003-06-24 Johnson & Johnson Uso de derivados de anticonvulsivos para tratar la bulimia nerviosa.
NZ513643A (en) 1999-02-24 2005-04-29 Univ Cincinnati Use of sulfamate derivatives for treating impulse control disorders
AU4050100A (en) 1999-04-08 2000-11-14 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing

Also Published As

Publication number Publication date
CA2446641A1 (en) 2002-11-21
JP2004533445A (ja) 2004-11-04
NO20035037L (no) 2004-01-07
HUP0400032A3 (en) 2012-09-28
PL367362A1 (en) 2005-02-21
HRP20030894A2 (en) 2004-06-30
MXPA03010406A (es) 2004-05-05
WO2002092071A1 (en) 2002-11-21
YU89103A (sh) 2006-08-17
KR20040028758A (ko) 2004-04-03
NZ529613A (en) 2006-09-29
CZ20033379A3 (cs) 2004-12-15
EP1392273A4 (en) 2004-11-24
US20020169103A1 (en) 2002-11-14
HUP0400032A2 (hu) 2004-04-28
CN1509168A (zh) 2004-06-30
IL158761A0 (en) 2004-05-12
EP1392273A1 (en) 2004-03-03
NO20035037D0 (no) 2003-11-13
US6462084B1 (en) 2002-10-08
TWI313599B (en) 2009-08-21

Similar Documents

Publication Publication Date Title
DE50106600D1 (de) Verwendung von hydrophil modifizierten polyisocyanaten und polyurethanen als antiknitteradditiv für den heimbereich
BR0016652A (pt) Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo
AU2002366641A1 (en) Methods for inhibiting ocular processes
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
BR9813684A (pt) Processo para tratar o glaucoma glc1a, e, composição para controlar o glaucoma glc1a.
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
ATE506945T1 (de) Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität
DE60045751D1 (de) Therapeutische Behandlung androgenrezeptorbedingter Leiden
ID28916A (id) Pengobatan ketagihan dan perilaku yang berkaitan dengan ketagihan
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
EP1639141A4 (en) METHOD FOR THE TREATMENT OF LENTIVIRUS INFECTIONS
DE69834693D1 (de) Zusammensetzung zur behandlung von elastischen polyurethanfasern und die damit behandelten fasern
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
BR0111601A (pt) Método para o tratamento de doença cardiovascular
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
ATE359804T1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1- inhibitoren zur behandlung von nierenkrankheiten
EP1141251A4 (en) CONNECTIONS, SCREENING METHOD AND METHOD OF TREATING DISEASES OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM
YU89103A (sh) Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a
DE69602603D1 (de) Kontrollgerät für eine aus mehreren lasermodulen bestehende laserquelle zur energetischen und räumlichen optimierung während der laserbearbeitung von oberflächen
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
BR0114595A (pt) Uso de um composto que rompe esteróide sexual que sinaliza para o timo no tratamento de um distúrbio de células t
ATE404208T1 (de) Uridin-therapie für patienten mit erhöhten purin- werten
FR2825273B1 (fr) Composition pour le traitement des signes cutanes du vieillissement
ATE258793T1 (de) 5-ht2 agonisten als mittel zur kontrolle des augeninnendrucks und zur behandlung von glaukom
ATE299703T1 (de) Mmp-hemmer bei bindegewebserweichung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI.A61K 31/195, A61K 31/197, A61K 45/00, A61P 25/18, A61P 25/22, A61P 25/28, A61P 43/00

Ipc: A61K 31/195 (2011.01), A61K 31/197 (2011.01), A61K

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 10A ANUIDADE.